Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Bioinformatics Analysis of Global Diversity in Meningococcal Vaccine Antigens over the Past 10 Years; Vaccine Efficiency Prognosis

Version 1 : Received: 15 November 2023 / Approved: 15 November 2023 / Online: 15 November 2023 (14:29:43 CET)

A peer-reviewed article of this Preprint also exists.

Savitskaya, V.Y.; Dolinnaya, N.G.; Strekalovskikh, V.V.; Peskovatskova, E.S.; Snyga, V.G.; Trefilov, V.S.; Monakhova, M.V.; Kubareva, E.A. Bioinformatics Analysis of Global Diversity in Meningococcal Vaccine Antigens over the Past 10 Years: Vaccine Efficacy Prognosis. Med. Sci. 2023, 11, 76. Savitskaya, V.Y.; Dolinnaya, N.G.; Strekalovskikh, V.V.; Peskovatskova, E.S.; Snyga, V.G.; Trefilov, V.S.; Monakhova, M.V.; Kubareva, E.A. Bioinformatics Analysis of Global Diversity in Meningococcal Vaccine Antigens over the Past 10 Years: Vaccine Efficacy Prognosis. Med. Sci. 2023, 11, 76.

Abstract

Neisseria meningitidis (N. meningitidis) serogroup B (MenB) is the leading cause of invasive meningococcal disease worldwide. The pathogen has a wide range of virulence factors, which are potential vaccine components. Studying the genetic variability of antigens within a population, especially their long-term persistence, is necessary to develop new vaccines and predict the effectiveness of existing ones. The multicomponent 4CMenB vaccine (Bexsero), used since 2014, contains three major genome-derived recombinant proteins: factor H-binding protein (fHbp), Neisserial Heparin-Binding Antigen (NHBA) and Neisserial adhesin A (NadA). Here, we assessed the prevalence and sequence variations of these vaccine antigens in a panel of 5667 meningococcal isolates collected worldwide over the past 10 years and deposited in the PubMLST database. Using multiple amino acid sequence alignments and machine learning methods, we estimated the potential strain coverage by fHbp and NHBA vaccine variants (51 and about 30%, respectively); the NadA antigen sequence was found in only 17.8% of MenB genomes analyzed, but cross-reactive variants were present in less than 1% of isolates. Based on our findings, we proposed various strategies to improve the 4CMenB vaccine and broaden coverage of N. meningitidis strains.

Keywords

Neisseria meningitidis serogroup B; meningococcal vaccine; bioinformatics tools; machine learning methods; multiple amino acid sequence alignments

Subject

Biology and Life Sciences, Biochemistry and Molecular Biology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.